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Purpose of the study
Raltegravir (RAL) is the first approved HIV integrase
inhibitor and has demonstrated potent efficacy in both
treatment-experienced and -naïve HIV-infected patients
(pts). This analysis reports long-term efficacy data from
one Phase II and two Phase III studies in pts infected with
non-B subtype virus.
Methods
Each study was double-blind and randomized; all pts
received a background ART regimen (see table in Figure
1). Primary results have been presented for each study.
Protocol (P) 004 in treatment-naïve pts was a dose-rang-
ing study of RAL vs. efavirenz (EFV) until week 48 after
which all pts in RAL groups received 400 mg BID.
BENCHMRK-1 and -2 were identical Phase III studies
using RAL at 400 mg BID vs. placebo (PBO) in highly
treatment-experienced pts with multi-drug resistant virus
failing other therapies. Each of the three studies showed
potent clinical efficacy for RAL-treated pts. In this analysis,
P004 results are shown for all RAL dose groups combined
at week 96, and BENCHMRK-1 and -2 results are shown
combined at week 48. Non-B subtypes were combined for
the analyses due to small numbers of each specific non-B
subtype.
Summary of results
In total, 622 pts were randomized to RAL and 275 to com-
parator across the three studies. Non-B subtype virus was
isolated at baseline in 62 pts in the RAL groups (23 from
P004), and in 23 pts in the comparator groups (8 from
P004). Subtypes AE and D were most common, isolated
in 40 and eight pts, respectively. Data are available for 58/
62 and 22/23 of pts with non-B subtype virus using the
observed failure approach for % with RNA < 50 copies/mL
(see table in Figure 1). RAL-treated pts demonstrated
increases from baseline in CD4 of 216 and 250 cells/mm3
for B and non-B, respectively, at week 96 in P004, and of
105 and 150 cells/mm3, for B and non-B, respectively, at
week 48 in BENCHMRK-1 and -2.
Conclusion
In these studies, RAL showed similar and potent clinical
efficacy in patients with B subtype and non-B subtype HIV
in both treatment-naïve and treatment-experienced popu-
lations.
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